Last reviewed · How we verify

polidocanol injectable foam, 1.0%

Boston Scientific Corporation · Phase 3 active Small molecule

polidocanol injectable foam, 1.0% is a sclerosing agent Small molecule drug developed by Boston Scientific Corporation. It is currently in Phase 3 development for Treatment of varicose veins and spider veins.

Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure.

Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure. Used for Treatment of varicose veins and spider veins.

At a glance

Generic namepolidocanol injectable foam, 1.0%
SponsorBoston Scientific Corporation
Drug classsclerosing agent
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

This process is thought to occur through the formation of a thrombus, which eventually leads to the occlusion of the treated vein. The exact molecular mechanisms underlying this process are not fully understood.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about polidocanol injectable foam, 1.0%

What is polidocanol injectable foam, 1.0%?

polidocanol injectable foam, 1.0% is a sclerosing agent drug developed by Boston Scientific Corporation, indicated for Treatment of varicose veins and spider veins.

How does polidocanol injectable foam, 1.0% work?

Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure.

What is polidocanol injectable foam, 1.0% used for?

polidocanol injectable foam, 1.0% is indicated for Treatment of varicose veins and spider veins.

Who makes polidocanol injectable foam, 1.0%?

polidocanol injectable foam, 1.0% is developed by Boston Scientific Corporation (see full Boston Scientific Corporation pipeline at /company/boston-scientific-corporation).

What drug class is polidocanol injectable foam, 1.0% in?

polidocanol injectable foam, 1.0% belongs to the sclerosing agent class. See all sclerosing agent drugs at /class/sclerosing-agent.

What development phase is polidocanol injectable foam, 1.0% in?

polidocanol injectable foam, 1.0% is in Phase 3.

What are the side effects of polidocanol injectable foam, 1.0%?

Common side effects of polidocanol injectable foam, 1.0% include Pain, Swelling, Redness, Itching, Numbness.

Related